目的:评估BRCA1/2基因突变状态与卵巢癌患者临床特征的相关性及对预后的影响。方法:选取2017年11月—2022年6月在兰州大学第一医院进行治疗的51例接受BRCA1/2基因检测的卵巢癌患者作为研究对象,根据检测结果分为BRCA1/2突变组(30例)和BR...目的:评估BRCA1/2基因突变状态与卵巢癌患者临床特征的相关性及对预后的影响。方法:选取2017年11月—2022年6月在兰州大学第一医院进行治疗的51例接受BRCA1/2基因检测的卵巢癌患者作为研究对象,根据检测结果分为BRCA1/2突变组(30例)和BRCA1/2正常组(21例)。比较2组患者的临床基线资料、临床病理特征和预后,分析影响BRCA1/2基因突变的卵巢癌患者预后的相关因素。结果:BRCA1/2突变组与BRCA1/2正常组相比,发病年龄、体质量指数(body mass index,BMI)、恶性肿瘤家族史、治疗前糖类抗原125(carbohydrate antigen 125,CA125)及人附睾蛋白4(human epididymis protein 4,HE4)差异均无统计学意义(均P>0.05)。BRCA1/2突变组与BRCA1/2正常组肿瘤分期及淋巴结转移情况比较,差异有统计学意义(P<0.05)。多因素Cox回归分析显示BRCA1/2基因突变不是卵巢癌生存率及无进展生存期的独立预后因素(HR=0.752,95%CI:0.394~1.435,P=0.329)。结论:BRCA1/2基因突变是决定卵巢癌患者临床治疗的重要因素,与肿瘤分期及淋巴结转移情况显著相关,但仍不能确定BRCA1/2基因突变是卵巢癌的独立危险因素。展开更多
目的探讨BRCA1相关蛋白1(BAP1)在肝细胞肝癌(LIHC)中的表达变化及其与预后的关系。方法从UALCA获得癌症基因组图谱(TCGA)中LIHC的BAP1 m RNA表达水平及临床数据并进行数据分组和处理。采用R3.2.2软件进行分析。比较BAP1在癌组织与正常...目的探讨BRCA1相关蛋白1(BAP1)在肝细胞肝癌(LIHC)中的表达变化及其与预后的关系。方法从UALCA获得癌症基因组图谱(TCGA)中LIHC的BAP1 m RNA表达水平及临床数据并进行数据分组和处理。采用R3.2.2软件进行分析。比较BAP1在癌组织与正常组织中的表达差异,并分析LIHC患者各亚组临床指标的BAP1表达水平与正常组织的差异。采用寿命表法计算生存率,采用Kaplan-Meier法比较BAP1高表达组和中低表达组患者的生存率,并绘制患者的生存曲线。结果LIHC组织中BAP1 mRNA表达中位数为37.748 TPM,明显高于正常组织中的18.444 TPM,差异有显著统计学意义(P<0.01);患者的性别、年龄、种族、体质量、组织学类型、组织学分级、淋巴结、TNM分期Ⅰ~Ⅲ期、TP53突变的各组癌组织中BAP1表达水平与正常组织表达水平比较差异均有统计学意义(P<0.05),而Ⅳ期组癌组织中BAP1表达水平与正常组织表达水平比较差异无统计学意义(P>0.05);患者的中位生存时间为27.18个月,1年、2年、3年、4年、5年生存率分别为0.57%、0.31%、0.20%、0.13%、0.08%;BAP1 m RNA高表达的整体生存率较BAP1mRNA中低表达者短,差异均有统计学意义(P<0.05)。结论BAP1 m RNA在LIHC中呈高表达,高表达组生存率较低,提示预后不良。展开更多
Fibroids, also called leiomyomas or myomas, are communal tumors of the muscle or uterine wall that affect about 20% of females who are of reproductive age. They can look as if singly or in clusters, and they often cea...Fibroids, also called leiomyomas or myomas, are communal tumors of the muscle or uterine wall that affect about 20% of females who are of reproductive age. They can look as if singly or in clusters, and they often cease to grow after menopause. Fibroids can be classified as intramural, sub serosal, pedunculated, or submucosal based on where they are positioned in the uterus. Although fibroids are benign, they can grow quickly and cause a range of symptoms, such as pelvic pressure, heavy menstrual flow, and infertility. As a result, fibroids are a main reason behind hysterectomy surgeries. The majority of cases of breast cancer are ductal and lobular cancers, making it the second utmost common cancer in women international. Gene mutations like those in BRCA1 or BRCA2 knowingly raise the risk of breast and other cancers, typically with an earlier cancer onset. Cancer risk is influenced by a complex interplay of genetic abnormalities, environmental factors, and lifestyle selections. Further research into these relations is domineering. Although they are common in uterine leiomyomas, especially multiple leiomyomas, MED12 mutations do not significantly correlate with tumor size. These mutations have also been noticed in smooth muscle tumors and leiomyosarcomas, two other types of uterine cancer. The identification of MED12 mutations as the sole genetic abnormality originates in leiomyomas raises the opportunity of a role in the genesis of cancer. 10% - 15% of women who are of reproductive age have endometriosis, which grants serious difficulties because of its chronic nature and range of clinical symptoms. Even after effective surgeries, issues reoccur often, adding to the enormous financial burden. The effects of MED12 mutations have been experiential in recent studies examining the molecular causes of endometriosis-associated infertility, which have shown anomalies in cellular connections and signaling cascades. Computational techniques were used in this study to investigate LifeGreenTM’s potential to prevent uterine fibroids and breast cancer. The efficacy of LifeGreenTM as a preventive measure or a treatment for common gynecological matters was examined and modeled. We investigated the mechanisms underlying LifeGreenTM’s benefits in the treatment of uterine fibroids and breast cancer using computational techniques. Our research contributes to our understanding of its potential therapeutic benefits for women’s health.展开更多
文摘目的:评估BRCA1/2基因突变状态与卵巢癌患者临床特征的相关性及对预后的影响。方法:选取2017年11月—2022年6月在兰州大学第一医院进行治疗的51例接受BRCA1/2基因检测的卵巢癌患者作为研究对象,根据检测结果分为BRCA1/2突变组(30例)和BRCA1/2正常组(21例)。比较2组患者的临床基线资料、临床病理特征和预后,分析影响BRCA1/2基因突变的卵巢癌患者预后的相关因素。结果:BRCA1/2突变组与BRCA1/2正常组相比,发病年龄、体质量指数(body mass index,BMI)、恶性肿瘤家族史、治疗前糖类抗原125(carbohydrate antigen 125,CA125)及人附睾蛋白4(human epididymis protein 4,HE4)差异均无统计学意义(均P>0.05)。BRCA1/2突变组与BRCA1/2正常组肿瘤分期及淋巴结转移情况比较,差异有统计学意义(P<0.05)。多因素Cox回归分析显示BRCA1/2基因突变不是卵巢癌生存率及无进展生存期的独立预后因素(HR=0.752,95%CI:0.394~1.435,P=0.329)。结论:BRCA1/2基因突变是决定卵巢癌患者临床治疗的重要因素,与肿瘤分期及淋巴结转移情况显著相关,但仍不能确定BRCA1/2基因突变是卵巢癌的独立危险因素。
文摘目的探讨BRCA1相关蛋白1(BAP1)在肝细胞肝癌(LIHC)中的表达变化及其与预后的关系。方法从UALCA获得癌症基因组图谱(TCGA)中LIHC的BAP1 m RNA表达水平及临床数据并进行数据分组和处理。采用R3.2.2软件进行分析。比较BAP1在癌组织与正常组织中的表达差异,并分析LIHC患者各亚组临床指标的BAP1表达水平与正常组织的差异。采用寿命表法计算生存率,采用Kaplan-Meier法比较BAP1高表达组和中低表达组患者的生存率,并绘制患者的生存曲线。结果LIHC组织中BAP1 mRNA表达中位数为37.748 TPM,明显高于正常组织中的18.444 TPM,差异有显著统计学意义(P<0.01);患者的性别、年龄、种族、体质量、组织学类型、组织学分级、淋巴结、TNM分期Ⅰ~Ⅲ期、TP53突变的各组癌组织中BAP1表达水平与正常组织表达水平比较差异均有统计学意义(P<0.05),而Ⅳ期组癌组织中BAP1表达水平与正常组织表达水平比较差异无统计学意义(P>0.05);患者的中位生存时间为27.18个月,1年、2年、3年、4年、5年生存率分别为0.57%、0.31%、0.20%、0.13%、0.08%;BAP1 m RNA高表达的整体生存率较BAP1mRNA中低表达者短,差异均有统计学意义(P<0.05)。结论BAP1 m RNA在LIHC中呈高表达,高表达组生存率较低,提示预后不良。
文摘Fibroids, also called leiomyomas or myomas, are communal tumors of the muscle or uterine wall that affect about 20% of females who are of reproductive age. They can look as if singly or in clusters, and they often cease to grow after menopause. Fibroids can be classified as intramural, sub serosal, pedunculated, or submucosal based on where they are positioned in the uterus. Although fibroids are benign, they can grow quickly and cause a range of symptoms, such as pelvic pressure, heavy menstrual flow, and infertility. As a result, fibroids are a main reason behind hysterectomy surgeries. The majority of cases of breast cancer are ductal and lobular cancers, making it the second utmost common cancer in women international. Gene mutations like those in BRCA1 or BRCA2 knowingly raise the risk of breast and other cancers, typically with an earlier cancer onset. Cancer risk is influenced by a complex interplay of genetic abnormalities, environmental factors, and lifestyle selections. Further research into these relations is domineering. Although they are common in uterine leiomyomas, especially multiple leiomyomas, MED12 mutations do not significantly correlate with tumor size. These mutations have also been noticed in smooth muscle tumors and leiomyosarcomas, two other types of uterine cancer. The identification of MED12 mutations as the sole genetic abnormality originates in leiomyomas raises the opportunity of a role in the genesis of cancer. 10% - 15% of women who are of reproductive age have endometriosis, which grants serious difficulties because of its chronic nature and range of clinical symptoms. Even after effective surgeries, issues reoccur often, adding to the enormous financial burden. The effects of MED12 mutations have been experiential in recent studies examining the molecular causes of endometriosis-associated infertility, which have shown anomalies in cellular connections and signaling cascades. Computational techniques were used in this study to investigate LifeGreenTM’s potential to prevent uterine fibroids and breast cancer. The efficacy of LifeGreenTM as a preventive measure or a treatment for common gynecological matters was examined and modeled. We investigated the mechanisms underlying LifeGreenTM’s benefits in the treatment of uterine fibroids and breast cancer using computational techniques. Our research contributes to our understanding of its potential therapeutic benefits for women’s health.
